Apria, Inc. ( APR) Stock. Should you Buy or Sell? $ 37.50
0.00 (0.00 %)
Apria, Inc. AnalysisUpdated on 10-09-2022
|Volume Avg.||$435.04 thousand|
|Market Cap||$1.34 B|
|52 Week Range||$25.01 - $40.0|
Apria, Inc. opened the day at $37.50 which is 0.00 % on yesterday's close. Apria, Inc. has a 52 week high of $40.0 and 52 week low of $25.01, which is a difference of $14.99. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $1.34 B and total net profit is $1145275000 which means the company is trading at 1.17 times profit to market capitalization. Theoretically, if you were to buy Apria, Inc. for $1.34 B, it would take 15 years to get your money back. Apria, Inc. are in the Medical Instruments & Supplies space which will have a sweet spot and industry standard for net profit multiples.
Apria, Inc. Stock Forecast - Is Apria, Inc. a Buy or Sell?
|DCF Score||Strong Buy|
|ROE Score||Strong Buy|
|DE Score||Strong Buy|
|PE Score||Strong Buy|
|PB Score||Strong Buy|
|Overall Recommendation||Strong Buy|
Growth and Value
|Net Profit Margin||0.057|
Valuing Apria, Inc.
|Price Book Value Ratio||33.491||Price To Book Ratio||33.491|
|Price To Sales Ratio||1.162||Price Earnings Ratio||20.511|
How liquid is Apria, Inc.
|Debt Ratio||0.949||Debt Equity Ratio||18.516|
|Long Term Debt To Capitalization||0.907||Total Debt To Capitalization||0.919|
Latest news about Apria, Inc.
Quipt Convertible Debenture Hedging Provides An Incredible Opportunity
Healthcare technology company Owens & Minor Inc. OMI, +3.25% said Friday it has launched a private offering of $500 million of 8-year high-yield bonds. Proceeds will be used to fund the acquisition of Apria Inc. with any remaining money to be used for general corporate purposes.
Here is how Apria (APR) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Apria Inc (NASDAQ: APR) spiked 25% after it announced that it had entered a definitive agreement with Owens & Minor (NYSE: OMI) whereby Owens would acquire its common stock shares for $37.50 per share representing a total equity value of roughly $1.45 billion. The strategic rationale of the deal The deal is set to strengthen the […] The post Apria Inc up 25% after signing a definitive agreement with Owens & Minor appeared first on Invezz.
Owens & Minor, Inc. (NYSE: OMI) announced it is buying Apria, Inc. (Nasdaq: APR) for $1.45 billion. These are the details The post Why Owens & Minor (OMI) Is Buying Apria (APR) For $1.45 Billion appeared first on Pulse 2.0.
About Apria, Inc.
Apria, Inc. provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products. It also provides a range of home medical equipment and other products, and services for patients with home care needs; and clinical and administrative support services, and related products and supplies to patients. Apria, Inc. was incorporated in 2018 and is headquartered in Indianapolis, Indiana. As of March 29, 2022, Apria, Inc. operates as a subsidiary of Byram Healthcare Centers, Inc.